Eli Lilly's Stock Outperforms S&P 500 Over the Past Decade Despite Rising Competition
Eli Lilly's stock has surged over 1,100% over the past decade, significantly outperforming the S&P 500's 230% gain. This growth is driven by strong sales of its GLP-1 drugs, Mounjaro and Zepbound, which saw sales increases of 99% and 175% in 2025, respectively. However, the company's high P/E ratio of 39x raises concerns about its valuation despite a recent drawdown.
Tickers: $LLY
Topics: Eli Lilly GLP-1 drugs P/E ratio pharmaceutical industry stock performance